1. P116 ATHENA (GOG-3020/ENGOT-ov45; EudraCT 2017–004557–17; NCT03522246): a randomised, double-blind, placebo-controlled, phase 3 study of the poly(ADP-Ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer (OC). (1st November 2019) Authors: Christopoulou, A; Marmé, F; Oaknin, A; Lorusso, D; Safra, T; Lindahl, G; Chudecka-Glaz, A; Ciuleanu, T; Collins, DC; Demirkiran, F; Lifrenko, I; Van Gorp, T; Coleman, RL; Fujiwara, K; Oza, AM; Westin, SN; O'Malley, DM; Herzog, TJ; Eskander, R; Wilson, M Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A130 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗